163 related articles for article (PubMed ID: 1937083)
21. [10 years' experience with ruthenium 106/rhodium 106 treatment of malignant melanoma of the choroid--report on 264 irradiated tumors].
Guthoff R; von Domarus D; Steinhorst U; Hallermann D
Klin Monbl Augenheilkd; 1986 Jun; 188(6):576-83. PubMed ID: 3531691
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
23. Results of 106Ru/Rh-radiation of choroidal melanomas.
Busse H; Müller RP; Kroll P
Ann Ophthalmol; 1983 Dec; 15(12):1146-9. PubMed ID: 6660694
[TBL] [Abstract][Full Text] [Related]
24. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
[TBL] [Abstract][Full Text] [Related]
25. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience.
Lommatzsch PK
Br J Ophthalmol; 1986 Nov; 70(11):844-51. PubMed ID: 3790487
[TBL] [Abstract][Full Text] [Related]
26. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.
Wilson MW; Hungerford JL
Ophthalmology; 1999 Aug; 106(8):1579-87. PubMed ID: 10442907
[TBL] [Abstract][Full Text] [Related]
27. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.
Flühs D; Anastassiou G; Wening J; Sauerwein W; Bornfeld N
Med Phys; 2004 Jun; 31(6):1481-8. PubMed ID: 15259651
[TBL] [Abstract][Full Text] [Related]
28. Histopathology of enucleated intraocular melanomas irradiated with cobalt and ruthenium plaques.
Fuchs U; Kivelä T; Tarkkanen A; Laatikainen L
Acta Ophthalmol (Copenh); 1988 Jun; 66(3):255-66. PubMed ID: 10994445
[TBL] [Abstract][Full Text] [Related]
29. [A beta ray applicator (106Ru/106Rh) in the treatment of ciliary body melanomas].
Ballin R; Lommatzsch PK; Drost H; Ratajek B
Klin Monbl Augenheilkd; 1985 Aug; 187(2):144-6. PubMed ID: 4057906
[TBL] [Abstract][Full Text] [Related]
30. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.
Nag S; Quivey JM; Earle JD; Followill D; Fontanesi J; Finger PT;
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):544-55. PubMed ID: 12738332
[TBL] [Abstract][Full Text] [Related]
31. Clinical quality assurance for 106Ru ophthalmic applicators.
Kaulich TW; Zurheide J; Haug T; Nüsslin F; Bamberg M
Radiother Oncol; 2005 Jul; 76(1):86-92. PubMed ID: 15972240
[TBL] [Abstract][Full Text] [Related]
32. [A procedure for the determination of dose performance of radioactive eye applicators (106-Ru/106-Rh) and their significance for indications and treatment in malignant choroid melanomas].
Menapace R; Binder W
Klin Monbl Augenheilkd; 1985 Nov; 187(5):451-4. PubMed ID: 4087812
[TBL] [Abstract][Full Text] [Related]
33. Malignant melanomas of the choroid and ruthenium applicators.
Huyghe JP; Verbraeken H; Goes F; De Wilde G; Hanssens M; Brabant P; Van Hijfte R; De Laey JJ
Bull Soc Belge Ophtalmol; 1990; 238():137-43. PubMed ID: 2131116
[TBL] [Abstract][Full Text] [Related]
34. Clinical Predictors of Regression of Choroidal Melanomas after Brachytherapy: A Growth Curve Model.
Rashid M; Heikkonen J; Singh AD; Kivelä TT
Ophthalmology; 2018 May; 125(5):747-754. PubMed ID: 29499831
[TBL] [Abstract][Full Text] [Related]
35. Dosimetry of 106Ru eye applicators with a p-type silicon detector.
Lax I
Phys Med Biol; 1991 Jul; 36(7):963-72. PubMed ID: 1886930
[TBL] [Abstract][Full Text] [Related]
36. Does escalation of the apical dose change treatment outcome in beta-radiation of posterior choroidal melanomas with 106Ru plaques?
Hermann RM; Pradier O; Lauritzen K; Ott M; Schmidberger H; Hess CF
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1360-6. PubMed ID: 11955750
[TBL] [Abstract][Full Text] [Related]
37. [The role of beta-ray therapy in the treatment of choroidal and ciliary body melanomas].
Grange JD; Gérard JP; Ragab M; Delaroche G; Jean-Louis B; Bievelez B; Sentenac I; Baute B
Ophtalmologie; 1989; 3(3):175-9. PubMed ID: 2641104
[TBL] [Abstract][Full Text] [Related]
38. Echographic evaluation of choroidal melanomas treated with ruthenium-106 plaques: the treatment failures.
Perri P; Police G; Pastena B; Ravalli L; Grande L; Rossi A
Ophthalmologica; 1998; 212 Suppl 1():33-6. PubMed ID: 9730745
[TBL] [Abstract][Full Text] [Related]
39. Results of ruthenium irradiation of uveal melanoma.
Tjho-Heslinga RE; Kakebeeke-Kemme HM; Davelaar J; de Vroome H; Bleeker JC; Oosterhuis JA; Leer JW
Radiother Oncol; 1993 Oct; 29(1):33-8. PubMed ID: 8295985
[TBL] [Abstract][Full Text] [Related]
40. Results of contact beta-irradiation of choroidal melanomas.
Damjanovich J; Berta A; Vezendi L
Acta Chir Hung; 1997; 36(1-4):67-8. PubMed ID: 9408291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
